Cochrane · systematic review · CD010736
Oxandrolone for growth hormone‐treated girls aged up to 18 years with Turner syndrome
Mohamed, S, Alkofide, H, Adi, YA, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
Metabolic and Endocrine DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
4
No studies
2
Included studies
NR
No studies 2 · 28.6%Ungraded 1 · 14.3%Very low 2 · 28.6%Low 1 · 14.3%Moderate 1 · 14.3%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Oxandrolone for growth hormone‐treated girls aged up to 18 years with Turner syndrome
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Improvement in final adult height (cm) | no estimate extracted | 5 studies · 270 participants | Moderate Downgraded: imprecision |
Adverse events (N) | RR 1.81 [0.83, 3.96] | 2 studies · 170 participants | Low Downgraded: imprecision |
Health‐related quality of life | no estimate extracted | NR | No studies |
Effects on speech (voice frequency) | no estimate extracted | 0 participants | Ungraded |
Effects on cognition(WISC‐R questionnaire) | no estimate extracted | 1 study · 51 participants | Very low Downgraded: imprecision, inconsistency |
Effects on psychological status (several questionnaires) | no estimate extracted | 1 study · 106 participants | Very low Downgraded: imprecision, inconsistency |
All‐cause mortality | no estimate extracted | NR | No studies |